Associations - VEGF-A inhibitor

BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	bevacizumab Sensitive: C2 – Inclusion Criteria J Geriatr Oncol - 2 weeks (New C3) bevacizumab Sensitive : C2 J Geriatr Oncol - 2wk	bevacizumab Sensitive: C2 – Inclusion Criteria J Geriatr Oncol - 2 weeks bevacizumab Sensitive : C2 J Geriatr Oncol - 2 weeks - (New C3)
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1
BRCA1 mutation	Peritoneal Cancer	BRCA1 mutation	Peritoneal Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
BRCA2 mutation	Peritoneal Cancer	BRCA2 mutation	Peritoneal Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
BRCA2 mutation	Fallopian Tube Cancer	BRCA2 mutation	Fallopian Tube Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
BRCA1 mutation	Fallopian Tube Cancer	BRCA1 mutation	Fallopian Tube Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
HRD	Fallopian Tube Cancer	HRD	Fallopian Tube Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
HRD	Peritoneal Cancer	HRD	Peritoneal Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval Byvasda (bevacizumab biosimilar) Sensitive : A1	Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval Byvasda (bevacizumab biosimilar) Sensitive : A1
HRD	Ovarian Cancer	HRD	Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : C1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : C1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : C1	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : C1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : C1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : C1
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : C1	bevacizumab + olaparib Sensitive: A1 - Approval bevacizumab + olaparib Sensitive : C1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval Aybintio (bevacizumab biosimilar) Sensitive : A1
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Rectal Cancer	No biomarker	Rectal Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1

VEGF-A inhibitor

VEGF-A inhibitor

Associations(476)

Associations
(476)